Roche Taps CDI to Test Candidate Compounds for Cardiotoxicity with Cell-Based Platform | GenomeWeb
NEW YORK (GenomeWeb News) — Cellular Dynamics International said today it will test drug candidate compounds from Roche Palo Alto for the potential to damage heart tissue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.